Explore results from the PAPZIMEOS clinical study
PAPZIMEOS may help people with RRP stop replaying surgery after surgery
PAPZIMEOS is recommended as a first-line treatment for adult patients with RRP.
1 year after treatment with PAPZIMEOS
Over half had zero surgeries
Some people with RRP went from having at least 3 surgeries per year before taking PAPZIMEOS to 0 surgeries in the year after finishing treatment.
Still surgery free
Most people surgery free at year 1 did not need surgery after 2 years (15 of 18).
Surgery free for even longer
All people who were surgery free after 2 years (15 of 18) were still surgery free after a median follow-up of 3 years (range, 36-51 months).
Still surgery free at 4 years
5 of the 18 people reached 4 years with no surgical interventions. The study is still ongoing.
5-year follow-up is ongoing
Among the 38 patients monitored for side effects in the clinical study, the most commonly reported side effects were pain, redness, or swelling where the shot was given, along with tiredness, chills, fever, muscle aches, nausea (feeling sick), headache, increased heart rate, diarrhea, vomiting, and sweating a lot.
Learn more about RRP and how PAPZIMEOS may be able to help.
Download thePatient Brochure
PAPZIMEOS reduced the overall number of surgeries
1 year after treatment with PAPZIMEOS
Some people with RRP went from having at least 3 surgeries a year before PAPZIMEOS to zero after finishing treatment. The 35 patients in the study who received the recommended dose had 152 surgeries total in the year before treatment—and only 46 in the year after.
Do you still have questions about RRP or the way PAPZIMEOS works?
See the Discussion GuideThe most common side effects of PAPZIMEOS included*:
- Pain, redness, or swelling where the shot was given
- Feeling tired
- Chills
- Fever
- Muscle aches
- Nausea (feeling sick)
- Headache
- Increased heart rate
- Diarrhea
- Vomiting
- Sweating a lot
*Safety evaluation included all 38 people with RRP studied who received PAPZIMEOS. 35 people in the clinical study received the recommended dose of PAPZIMEOS.
No patients in the clinical trial had to stop taking PAPZIMEOS early due to side effects
Most adverse reactions happened after the first dose of PAPZIMEOS and usually lasted 1-3 days.
In people who took PAPZIMEOS, the most common adverse reactions were mild to moderate and mostly resolved on their own.
These are not all of the possible side effects of PAPZIMEOS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Precigen, Inc. at 1-855-PGE-NRRP (1-855-743-6777).
Learn about what to expect when starting PAPZIMEOS
Read more about what to expectSign up for Papzimeos SUPPORT today
Enroll now